Theranostics in Nuclear Medicine: Therapy to Impact Patient Management and Secure the Future in the era of precision oncology

Abstract

Author(s): Sachin Pradhan, Chetan Kumar Sonkar

Precision oncology has become a revolutionary strategy in cancer treatment, providing personalized patient care by considering their unique genetic, molecular, and clinical attributes. The technique has significantly reshaped the cancer detection and therapy domain, emphasizing the pivotal significance of Theranostics in Nuclear Medicine (TNM). The integration of diagnostics and therapeutics in TNM represents a significant advancement in nuclear medicine imaging since it enables the implementation of tailored medicines for the precise management of tumors. The relevance of this approach is in its ability to provide patients with individualized treatment programs via the identification of particular molecular targets, therefore reducing the occurrence of side effects and improving therapeutic results. Although the advantages of using the TNM system in precision oncology are indisputable, some obstacles must be addressed. The presence of heterogeneity among cancer cells, coupled with the inherent constraints of targeted treatment, necessitates the development of new alternatives. Recent developments in the field of TNM have shown encouraging results, including the use of Lutetium therapy for the treatment of prostate cancer, Yttrium-90 SIRT therapy for liver cancer, and Iodine-131 therapy for thyroid diseases. The medicines have shown noteworthy outcomes, emphasizing the potential of TNM in enhancing healthcare provision to patients. The experimental findings provide further evidence supporting the effectiveness of TNM, as demonstrated by significant improvements in key metrics such as signalto-noise ratio, contrast-to-noise ratio, Image Spatial Resolution, and Lesion Detection Sensitivity. The results support the use of TNM as a crucial instrument in improving patient care and safety by administering focused medication while minimizing adverse effects

Share this article

Awards Nomination

Editors List

  • Prof. Elhadi Miskeen

    Obstetrics and Gynaecology Faculty of Medicine, University of Bisha, Saudi Arabia

  • Ahmed Hussien Alshewered

    University of Basrah College of Medicine, Iraq

  • Sudhakar Tummala

    Department of Electronics and Communication Engineering SRM University – AP, Andhra Pradesh

     

     

     

  • Alphonse Laya

    Supervisor of Biochemistry Lab and PhD. students of Faculty of Science, Department of Chemistry and Department of Chemis

     

  • Fava Maria Giovanna

     

Google Scholar citation report
Citations : 208

Onkologia i Radioterapia received 208 citations as per Google Scholar report

Onkologia i Radioterapia peer review process verified at publons
Indexed In
  • Directory of Open Access Journals
  • Scimago
  • SCOPUS
  • EBSCO A-Z
  • MIAR
  • Euro Pub
  • Google Scholar
  • Medical Project Poland
  • PUBMED
  • Cancer Index
  • Gdansk University of Technology, Ministry Points 20